Transportation Update Actualización de transporte

SafeRide Health (SRH) is the new provider for all NEMT rides to doctor appointments and pharmacy visits.

Depending on your needs, rides may include wheelchair-lift-equipped vehicles, stretcher vans, minivans, or ambulatory vans. Please let SRH know what type of ride you need when scheduling.

Learn more

SafeRide Health (SRH) es el nuevo proveedor de todos los servicios de transporte médico que no son de emergencia (NEMT, por sus siglas en inglés) hacia consultas médicas y farmacias.

Según tus necesidades, los servicios de transporte pueden incluir vehículos con elevador para sillas de ruedas, camionetas con camilla, minivans o camionetas ambulatorias. Por favor, informa a SRH qué tipo de transporte necesitas al programar tu traslado.

Obtenga más información AQUI

Conduent Incident Incidente de Conduent

Search

Annual Review of Clinical Prior Authorization Criteria Guides

Date: November 14, 2022Attention: ProvidersEffective date: November 29, 2022Providers should monitor the Texas Children’s Health Plan (TCHP) Provider Portal regularly for alerts and updates associated to the COVID-19 event.  TCHP reserves the right to update and/or change this information without prior notice due to the evolving nature of the COVID-19 event. Call to action: Texas Children’s Health Plan (TCHP) will revise the following clinical prior authorization criteria: Epidiolex, GLP-1 Receptor Agonists, Lovaza & Vascepa by November 29, 2022. The changes will be as follows:
  • Epidiolex: TCHP will expand coverage of Epidiolex to treatment resistant seizures
  • GLP-1 Receptor Agonists: TCHP will add medullary thyroid carcinoma (MTC) and multiple endocrine neoplasia syndrome type 2 (MEN 2) to the list of contraindications
  • Lovaza & Vascepa: TCHP will expand coverage of Vascepa to members with elevated triglcyerides levels (TG> 150mg/dl) and Diabetes mellitus or established cardiovascular disease.
How this impacts providers: Prior authorization criteria for Epidiolex will be the following:
  1. Does the client have paid claims for greater than or equal to (≥) 60 days of cannabidiol (Epidiolex) in the last 90 days?
[] Yes (Approve – 365 days) [] No (Go to #2)  
  1. Is the client greater than or equal to (≥) 1 year of age?
[] Yes (Go to #3) [] No (Deny)  
  1. Does the client have a diagnosis of Lennox-Gastaut syndrome, Dravet syndrome or tuberous sclerosis complex in the last 730 days?
[] Yes (Approve – 365 days) [] No (Go to #4)  
  1. Does the client have a history of paid claims for at least 2 other anticonvulsant agents (other than cannabidiol, Epidiolex), each for greater than or equal to (≥) 30 days in the last 365 days?
[] Yes (Approve – 365 days) [] No (Deny)   Prior authorization criteria for GLP-1 Receptor Agonists will be the following:
  1. Is the client greater than or equal to (≥) 18 years of age?
[ ] Yes (Go to #3) [ ] No (And request is for Bydureon BCise or Victoza, go to #2) [ ] No (And request is for any agent other than Bydureon BCise or Victoza, deny)
  1. Is the client greater than or equal to (≥) 10 years of age?
[ ] Yes (Go to #3) [ ] No (Deny)
  1. Does the client have a diagnosis of type 2 diabetes in the last 365 days?
[ ] Yes (Go to #4) [ ] No (Deny)
  1. Does the client have a history of an oral antidiabetic agent for 14 days in the last 365 days?
[ ] Yes (Go to #7) [ ] No (Go to #5)
  1. Does the client have a history of the requested medication for 14 days in the last 365 days?
[ ] Yes (Go to #7) [ ] No (Go to #6)
  1. Does the client have a history of atherosclerotic cardiovascular disease (ASCVD), heart failure (HF) or chronic kidney disease (CKD) in the last 365 days?
[ ] Yes (Go to #7) [ ] No (Deny)
  1. Does the client have a history of ESRD, pancreatitis, gastroparesis, medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN 2) in the last 730 days?
[ ] Yes (Deny) [ ] No (Go to #8)
  1. Does the client have a history of ESRD services (CPT codes) in the last 730 days?
[ ] Yes (Deny) [ ] No (Go to #9)
  1. Does the client have a history of an HbA1c test in the last 180 days?
[ ] Yes (Go to #10) [ ] No (Deny)
  1. Will the client have concurrent therapy with a GLP-1 RA containing agent?
[ ] Yes (Deny) [ ] No (Approve – 365 days) Prior authorization criteria for Lovaza & Vascepa will be the following:
  1. Is the client greater than or equal to (³) 18 years of age?
[ ] Yes (Go to #2) [ ] No (Deny)
  1. Does the client have a diagnosis of severe hypertriglyceridemia (TG ≥ 500mg/dL) in the last 365 days?
[ ] Yes (Go to #3) [ ] No (And the request is for Vascepa, go to #4) [ ] No (Deny)
  1. Has the patient failed a 30-day treatment trial with a fibrate in the last 180 days?
[ ] Yes (Go to #6) [ ] No (Deny)
  1. Does the client have a diagnosis of elevated triglyceride levels (TG ≥ 150mg/dL) AND diabetes mellitus or established cardiovascular disease?
[ ] Yes (Go to #5) [ ] No (Deny)
  1. Is the client currently on maximally tolerated statin therapy, or does the client have an intolerance or contraindication to statin therapy?
[ ] Yes (Go to #6) [ ] No (Deny)
  1. Is the quantity requested less than or equal to (£) 4 units per day?
[ ] Yes (Approve – 365 days) [ ] No (Deny)   Next steps for providers: Prescribers can find updated prior authorization for on Navitus page.  Prescribers should share this update with their staff   If you have any questions, please email Provider Relations at: providerrelations@texaschildrens.org.For access to all provider alerts,log into: www.thecheckup.org or www.texaschildrenshealthplan.org/for-providers